HK1037141A1 - Use of endothelin receptor antagonists for producing drugs for controlling obesity. - Google Patents

Use of endothelin receptor antagonists for producing drugs for controlling obesity.

Info

Publication number
HK1037141A1
HK1037141A1 HK01107896A HK01107896A HK1037141A1 HK 1037141 A1 HK1037141 A1 HK 1037141A1 HK 01107896 A HK01107896 A HK 01107896A HK 01107896 A HK01107896 A HK 01107896A HK 1037141 A1 HK1037141 A1 HK 1037141A1
Authority
HK
Hong Kong
Prior art keywords
receptor antagonists
endothelin receptor
controlling obesity
producing drugs
obesity
Prior art date
Application number
HK01107896A
Other languages
English (en)
Inventor
Klaus Munter
Michael Kirchengast
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Ag filed Critical Knoll Ag
Publication of HK1037141A1 publication Critical patent/HK1037141A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK01107896A 1997-12-05 2001-11-09 Use of endothelin receptor antagonists for producing drugs for controlling obesity. HK1037141A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19754082A DE19754082A1 (de) 1997-12-05 1997-12-05 Methode zur Bekämpfung der Fettleibigkeit
PCT/EP1998/007501 WO1999029308A2 (de) 1997-12-05 1998-11-21 Methode zur bekämpfung der fettleibigkeit

Publications (1)

Publication Number Publication Date
HK1037141A1 true HK1037141A1 (en) 2002-02-01

Family

ID=7850913

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01107896A HK1037141A1 (en) 1997-12-05 2001-11-09 Use of endothelin receptor antagonists for producing drugs for controlling obesity.

Country Status (17)

Country Link
US (1) US6197780B1 (xx)
EP (1) EP1035851B1 (xx)
JP (1) JP2002512173A (xx)
KR (1) KR20010032779A (xx)
CN (1) CN1152685C (xx)
AT (1) ATE204172T1 (xx)
AU (1) AU751053B2 (xx)
BR (1) BR9815335A (xx)
CA (1) CA2311423C (xx)
CZ (1) CZ300442B6 (xx)
DE (2) DE19754082A1 (xx)
ES (1) ES2162493T3 (xx)
HK (1) HK1037141A1 (xx)
HU (1) HUP0100171A3 (xx)
NO (2) NO324694B1 (xx)
RU (1) RU2292891C2 (xx)
WO (1) WO1999029308A2 (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19533023B4 (de) * 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
EP1130027A1 (de) * 2000-02-29 2001-09-05 Aventis Pharma Deutschland GmbH Memno-Peptide, Verfahren zu ihrer Herstellung und Verwendung derselben
US20050175667A1 (en) * 2004-02-10 2005-08-11 Wenda Carlyle Use of endothelin antagonists to prevent restenosis
JP2010536880A (ja) 2007-08-22 2010-12-02 ギリード・コロラド・インコーポレーテッド 糖尿病の合併症のための療法
TWI701253B (zh) * 2011-11-11 2020-08-11 美商基利阿波羅有限責任公司 Ａｃｃ抑制劑及彼等之用途
EA201700155A1 (ru) * 2014-10-20 2017-10-31 Товарищество С Ограниченной Ответственностью "Фармацевтическая Компания "Ромат" Фармацевтическая композиция для лечения туберкулеза
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
KR20180082557A (ko) 2015-11-25 2018-07-18 길리어드 아폴로, 엘엘씨 트리아졸 acc 억제제 및 그의 용도
CA3004798C (en) 2015-11-25 2023-10-31 Gilead Apollo, Llc Ester acc inhibitors and uses thereof
KR20180086191A (ko) 2015-11-25 2018-07-30 길리어드 아폴로, 엘엘씨 2,4-디옥소-1,4-디히드로티에노[2,3-d]피리미딘 유도체를 함유하는 살진균 조성물
BR112018010113B1 (pt) 2015-11-25 2022-06-14 Gilead Apollo, Llc Composto de pirazol útil como inibidor da acetil-coa carboxilase (acc)
CA3220447A1 (en) 2016-03-02 2017-09-08 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
JP6906626B2 (ja) 2017-03-28 2021-07-21 ギリアード サイエンシーズ， インコーポレイテッド 肝疾患を処置するための治療的組み合わせ

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0670320A4 (en) * 1992-12-01 1997-05-02 Green Cross Corp DERIVATIVE OF 1,8-NAPHTHYRIDIN-2-ONE AND USE OF THIS DERIVATIVE.
US5998468A (en) * 1995-08-24 1999-12-07 Warner-Lambert Company Furanone endothelin antagonists
JP3116347B2 (ja) * 1996-11-13 2000-12-11 田辺製薬株式会社 医薬組成物

Also Published As

Publication number Publication date
ATE204172T1 (de) 2001-09-15
RU2003138080A (ru) 2005-06-10
ES2162493T3 (es) 2001-12-16
WO1999029308A3 (de) 1999-09-30
NO20074419L (no) 2000-06-02
AU2153599A (en) 1999-06-28
CZ300442B6 (cs) 2009-05-20
AU751053B2 (en) 2002-08-08
US6197780B1 (en) 2001-03-06
DE19754082A1 (de) 1999-06-10
NO324694B1 (no) 2007-12-03
HUP0100171A2 (hu) 2003-02-28
BR9815335A (pt) 2000-10-17
KR20010032779A (ko) 2001-04-25
WO1999029308A2 (de) 1999-06-17
DE59801230D1 (de) 2001-09-20
CA2311423C (en) 2008-01-29
CN1152685C (zh) 2004-06-09
CN1301162A (zh) 2001-06-27
EP1035851B1 (de) 2001-08-16
RU2292891C2 (ru) 2007-02-10
JP2002512173A (ja) 2002-04-23
CA2311423A1 (en) 1999-06-17
EP1035851A2 (de) 2000-09-20
NO20002777L (no) 2000-06-02
NO20002777D0 (no) 2000-05-30
CZ20002006A3 (cs) 2000-11-15
HUP0100171A3 (en) 2003-10-28

Similar Documents

Publication Publication Date Title
HK1037141A1 (en) Use of endothelin receptor antagonists for producing drugs for controlling obesity.
EP1231218A3 (en) An appetite-suppressing peptide, its compositions and use
MY117251A (en) Use of central cannabinoid receptor antagonists for the preparation of drugs
PT1047781E (pt) Receptores de il-18
IL129968A (en) Use of cntf receptor activators for the manufacture of a medicament for a medicament for the treatment of obesity
NO20011759D0 (no) Flt4 (VEGFR-3) som målmateriale for tumor-avbildning og anti- tumor-terapi
WO1996019458A3 (en) Steroid receptor modulator compounds and methods
PL352367A1 (en) Glucagon antagonists/inverse agonists
ES2304795T3 (es) Anticuerpos agonistas para el receptor de trombopoyetina y sus usos terapeuticos.
AU9386398A (en) Cysteine rich receptors: trail
AR019671A1 (es) Uso de una cantidad terapeuticamente efectiva de (+) norcisaprida o una sal farmacologicamente aceptable de la misma sustancialmente libre de su (-)estereoisomero, para la preparacion de un medicamento
ZA969775B (en) Endothelin receptor antagonists.
EP1181555A4 (en) CANCER TREATMENT WITH ENDOTHELINE RECEPTOR ANTAGONISTS
BG109537A (en) FUNCTION MODULATORS OF RECEPTORS OF TNF / NGF RECIPE FAMILY AND OTHER PROTEINS
ES2112546T3 (es) Benz(b)azepina-2,5-dionas utiles en el tratamiento de trastornos neurodegenerativos.
MY134167A (en) Biphenylcarboxamides useful as lipid lowering agents
EP0759441A3 (en) Methods of treating neuropeptide Y-associated conditions
AU2675795A (en) Tbp2 fragments of the transferrine receptor of neisseria meningitidis
AU3745795A (en) Use of CCK-B receptor antagonists for the treatment of sleepdisorders
NZ337087A (en) C-terminal fragment of pancreatic lipase for hyperlipaemia, obesity, and cardiovascular disorders
EP1090994A3 (en) Peptide repeat immunogens
AU3087599A (en) Human appetite control by glucagon-like peptide receptor binding compounds
EP0754464A3 (en) Methods of treating neuropeptide Y-associated conditions
WO1995022609A3 (en) Human glutamate receptor proteins
ZA966552B (en) Endothelin receptor antagonists.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20141121